Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Form T today, would you bet against it?
seriously though,
I am guessing we get hit with dilution on any good news. Today should have been better for anyone holding.
I really felt smart adding @.075 yesterday.
Congratulations.
wow, look at the pps move...
I am hoping they have been selling shares on the open market as well.
$0.0767 1,000,000 OBB 16:01:24
0.0779 2,250,000 OBB 16:02:58
$0.0742 2,425,000 OBB 16:09:02
Camofi had their shares today?
Thank you ddls, I think we finally get it. You are an asset to this forum!
next runup started?
Where is the lawsuit news?
volume:6M, -8%
ugly.
maybe next year I'll get an opportunity to sell.
I told myself yesterday I would sell on a spike, but instead I bought.
They paint a great picture.
I got played for a fool twice now in the new year - bought at the highs.
I bought some more.
edit - we will see 10 and above today!
are these 'institutional investors' not the toxic financers?
for the office?
mutual fund?
UMGAWA ASK IS .08!
Three cases granted
The Supreme Court agreed on Friday to rule on the rights of non-Indian couples to adopt an Indian child over the objection of a parent who is a tribal member. That was one of three newly granted cases. The others deal with the remedy if a federal judge has some role in plea bargaining discussions, and a dispute among states over sharing the waters of a river that flows between them.
The adoption case (Adoptive Couple v. Baby Girl, docket 12-399) involves the competing rights to a child that may arise under the Indian Child Welfare Act of 1978. In this case, a South Carolina couple had adopted at birth the daughter of a young woman who was not a tribal member, but the child was considered to be an Indian because of her father’s tribal membership. The South Carolina couple had to give up the child after raising her for two years, because a state court ruled that the federal law took priority over state law. At issue in the case is the definition of “parent” under the federal law, including whether that includes an unwed father who only belatedly claimed parental rights.
The Justices agreed to hear an appeal by the federal government in United States v. Davila (12-167), testing what the remedy is to be in a plea-bargained criminal case when a federal judge had some role leading up to agreement on the plea deal. The Eleventh Circuit Court ruled that, if the judge (in this case, a magistrate judge) has any role whatsoever in the plea talks, the guilty plea that resulted must be thrown out. The government petition argued that the guilty plea should be overturned only if the judge’s participation had resulted in prejudice to the accused.
The third case the Court agreed to review has been pending at the Court for some time, because the Court had asked for the views of the Solicitor General. After the federal government agreed that the case should be heard, the Court accepted it. The case is Tarrant Regional Water District v. Herrmann (docket 11-889). The Court is expected to use the case to clarify the right of a state to claim its share of a water rights compact from the waters of the shared river as it flows through a neighboring state. Here, the growing metro complex of Fort Worth, Texas, contends that it needs to dip into the Oklahoma flow of the Red River to fulfill its guaranteed equal share under the Red River Compact. Oklahoma insists that Texas has no right to reach across the two states’ border to help fulfill its water needs.
Posted in Tarrant Regional Water District v. Herrmann, U.S. v. Davila, Adoptive Couple v. Baby Girl, Featured, Merits Cases
Recommended Citation: Lyle Denniston, Three cases granted, SCOTUSblog (Jan. 4, 2013, 2:15 PM), http://www.scotusblog.com/2013/01/three-cases-granted/
UMGAWA, LOL.
(ORDER LIST: 568 U.S.)
FRIDAY, JANUARY 4, 2013
ORDERS IN PENDING CASES
11-1425
MISSOURI V. McNEELY, TYLER G.
11-1447
KOONTZ, COY A. V. ST. JOHNS RIVER WATER MGMT.
The motions of the Solicitor General for leave to participate
in oral argument as amicus curiae and for divided argument are
granted.
11-1545
)
ARLINGTON, TX, ET AL. V. FCC, ET AL.
)
11-1547
)
CABLE, TELECOMMUNICATIONS & TECH V. FCC, ET AL.
The motion of respondent Cellco Partnership d/b/a Verizon
Wireless for divided argument is denied. The motion of
petitioner Cable, Telecommunications, and Technology Committee
of the New Orleans City Council for divided argument is denied.
12-98
DELIA, SEC., NC DEPT. OF H&HS V. E. M. A., ET AL.
The motion of the Solicitor General for leave to participate
in oral argument as amicus curiae and for divided argument is
granted.
CERTIORARI GRANTED
11-889
TARRANT REGIONAL WATER DISTRICT V. HERRMANN, RUDOLF J., ET AL.
The motion of City of Irving, Texas, et al. for leave to
file a brief as amici curiae is granted. The petition for a
writ of certiorari is granted.
12-167
UNITED STATES V. DAVILA, ANTHONY
The petition for a writ of certiorari is granted.
12-399
ADOPTIVE COUPLE V. BABY GIRL, ET AL.
The motion of petitioners for leave to file Appendix B under
1
seal is granted. The motion of Professors Joan Heifetz Hollinger, et al. for leave to file a brief as amici curiae is granted. The petition for a writ of certiorari is granted.
2
http://www.supremecourt.gov/orders/courtorders/010413zr_9ol1.pdf
I hope so.
what is moving the price today?
1.56M * .063 = $98, 280
What a pathetic PR:
Advanced Cell Technology, Inc. (OTC:ACTC) is moving on bullish momentum this morning as the stock gains on no news. Currently, the stock is up $.0021 (3.63%) bringing the trade price up around $.06 with close to 1.5 million shares exchanged. Can ACTC increase its support for more gains? Stick around.
it is my understanding that John Titor was featured in New Scientist.
http://en.wikipedia.org/wiki/John_Titor
thanks for the clarification.
still, actc is getting peoples attention.
big pharma and other stem companies copying actc.
more like .0705 and .0715
ACT Announces Approval to Treat Additional Stargardt’s Disease Patients with Higher RPE Dosage in Both U.S. and European Clinical Trials
Data and Safety Monitoring Board (DSMB) Process Streamlined in the Protocol; Could Accelerate Patient Enrollment and Treatment in European Trial
MARLBOROUGH, Mass. — October 9, 2012 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Company’s three ongoing clinical trials, has authorized the Company to move forward with enrollment and treatment of second and third additional patients with Stargardt’s macular dystrophy (SMD) in the second patient cohort of its U.S. trial for the condition. Additionally, the DSMB has authorized the Company to treat all three patients in the second cohort of its European trial for SMD.
The UK Medicines and Healthcare produces Regulatory Agency (MHRA) recently approved a protocol modification to the DSMB review, streamlining the process, allowing the company to treat the first patient in a new cohort if the DSMB has allowed this in the US study, and once clearance has been received in the US trial to treat the next two patients in the US cohort. This would also allow for treatment of the UK patients without an additional review by the DSMB. Moreover, according to the protocol for both trials, each patient in the second cohort will be injected with 100,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells, up from 50,000 in the first cohort.
“This authorization to treat the next five patients in the second, higher-dosage cohort in both our clinical trials for SMD represents a significant step forward for our clinical programs,” commented Gary Rabin, chairman and CEO of ACT. “We are also encouraged with the MHRA’s approval of the DSMB’s streamlined review process. Clearly this has the potential to help accelerate the pace of our European trial.”
ACT is conducting three clinical trials in the U.S. and Europe using hESC-derived RPE cells to treat forms of macular degeneration, SMD and dry age-related macular degeneration (dry AMD). Each trial will enroll a total of 12 patients, with cohorts of three patients each in an ascending dosage format, from 50,000 hESC-derived RPE cells in the first patient cohort to 200,000 in the last and final cohort. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry-AMD or SMD at 12 months, the study’s primary endpoint.
“We are eagerly anticipating treating these final two patients in the second cohort of our U.S. trial for SMD, and all three patients in the second cohort of our E.U. trial,” commented Robert Lanza, M.D., ACT’s chief scientific officer. “We are encouraged by the preliminary data in the first patient in this second, higher-dosage cohort and look forward to gathering more data.”
Further information about patient eligibility for ACT’s SMD studies in the U.S. and E.U. as well as its dry AMD study are available at www.clinicaltrials.gov, with the following Identifiers: NCT01345006 (U.S. SMD), NCT01469832 (E.U. SMD), and NCT01344993 (dry AMD).
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.
Contact:
Investors:
CEOcast, Inc., James Young, 212-732-4300
Press:
ACT Corporate Communications, Bill Douglass, 646-450-3615
or:
Russo Partners, Martina Schwarzkopf, Ph.D., 212-845-4292
http://www.advancedcell.com/news-and-media/press-releases/act-announces-approval-to-treat-additional-stargardtandrsquo-s-disease-patients-with-higher-rpe-dosage-in-both-us-and-european-clinical-trials/index.asp
whats going on?
of course I am holding. waiting for a squeeze next earnings.
Today is not going as expected?
they have their shares today? great...
shorts are gonna get squeezed again as long as earnings aren't bad.
I would buy more but I put all I had into it around $14, I thought that was a deal, lol.